Mums Finance

Just while there’s a slight lull in the self-righteous screams of a few posturing Americans over the Deepwater Horizon Oil Spill in the Gulf of Mexico in May, shall we at this point remind President Obama and US Attorney General Eric Holder of a little incident called the ‘Bhopal Disaster’ in India back in 1984…?

Maybe this has slipped the minds of a few American executives – but this tragedy in India at the hands of American Gas giant Union Carbide rates as the worst industrial catastrophe of all time. While Obama calls for British heads to roll over the BP oil spill, let’s revisit a few facts that he might do well to consider…

11 people killed in accident on oil rig leased by British company BP, resulting in 4 presidential visits, a $1.6bn clean-up bill and the establishment of a $20bn compensation fund in 2 months.

15,000+ people killed in accident at Indian Bhopal plant owned by American company Union Carbide, resulting in O presidential visits, O clean-up bill and just $470m compensation in 25 years.

Now, shall we say Pot. Kettle. Black…?

Popularity: 15% [?]

I really feel sorry for my son these days. He is 22 and has recently bought his very first car and is discovering exactly how expensive it is to be a young male driver aged under 25. He has been getting a lot of auto insurance quotes this past week and the quotes range from the sort-of-affordable to the downright-bloody-expensive.

In a way it is not fair but you can understand things from the insurance companies point of view. What surprises me is how much prices have gone up in the past 20 years but it always was pricey being young and a driver. His car has now become his number one priority and if anything it will teach him a few things about budgeting – so far I have not needed to say ‘I told you so’…

Popularity: 15% [?]

This is a sponsored guest post written by Editor Newswire on behalf of INVO Bioscience, Inc.. Post powered by Sponzai.

(BEVERLY, MA – EDITOR NEWSWIRE) – INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today the signing of an agreement with a South African distribution company Delfran Pharmaceuticals (http://www.delfran.co.za/). Delfran is a drug and medical device distribution company that is looking to bring the low cost INVO procedure into African nations, making infertility treatment affordable to the general public. CEO Katie Karloff stated, “The shortage of a cost effective treatment has left assistance for many couples simply out of reach. We believe that INVO Bioscience partnered with Delfran can bring an affordable infertility procedure to couples in many areas of Africa.”

Dr. Claude Ranoux, President and Chief Scientific Officer, traveled to Cape Town and Johannesburg, South Africa from February 7^th-17^th to perform distributor training.

Delfran Pharmaceuticals will have rights to distribute the INVOcell in the countries of South Africa, Madagascar, Seychelles, Mauritius, Namibia, Botswana, Mozambique, Kenya and Angola. The INVOcell product does not need registration in the African nations outlined in the agreement. The governments offer very little financial support for IVF and the vast majority of cases done are paid for privately. Delfran will look to introduce the INVO procedure first into South Africa and then plans to expand INVO into the other territories of Sub-Saharan Africa.

INVO is also happy to announce the birth of the first INVO babies in Colombia. The babies were born on February 15, 2010 to a couple who had been treated at the CECOLFES Center for Fertility in Colombia.

The mother had developed three Grade 1 embryos in her previous IVF attempt without achieving pregnancy. Due to her previous infertility history, after undergoing INVO she was transferred 3 embryos and this resulted in the birth of triplets. These triplets are a multiple pregnancy that occurred during the 50 patient study performed by CECOLFES. The two baby boys, baby girl and mother are doing well and were home from the Pereira Colombia hospital within a few days. Dr. Elkin Lucena, Laboratory Director of CECOLFES, said, “This is the beginning of a new era in ART and the beginning of more births that we’re expecting from INVO in the following weeks.”

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Popularity: 25% [?]